monoclonal antibody 105 Search Results


90
PhosphoSolutions threonine 1007
Immunoblotting shows that loss of CDKL5 reduces the level of phosphorylated KCC2 at serine 940 <t>(pKCC2-S940;</t> A, B) in the rostral cortex at P12. No significant alteration is found in protein expression of total KCC2, phosphorylated KCC2 at <t>threonine</t> <t>1007</t> <t>(pKCC2-T1007),</t> NKCC1 and GABA A receptor. The reduction of PSD-95 in Cdkl5 -/y pups (A, D), consistent with the findings reported previously, serves as a positive control. The protein expression was quantified by densitometry with Image J using GAPDH as a loading control. The results are derived from three litters and presented as mean ± SEM. ** p < 0.01, Student’s t- test.
Threonine 1007, supplied by PhosphoSolutions, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/monoclonal+antibody+105/Anti-Ki-67+Antibody/bio_rxiv__2020__03__09__983981-79-41-45
Average 90 stars, based on 1 article reviews
threonine 1007 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biogen Inc neutralizing anti-lc1 moab 1a
Immunoblotting shows that loss of CDKL5 reduces the level of phosphorylated KCC2 at serine 940 <t>(pKCC2-S940;</t> A, B) in the rostral cortex at P12. No significant alteration is found in protein expression of total KCC2, phosphorylated KCC2 at <t>threonine</t> <t>1007</t> <t>(pKCC2-T1007),</t> NKCC1 and GABA A receptor. The reduction of PSD-95 in Cdkl5 -/y pups (A, D), consistent with the findings reported previously, serves as a positive control. The protein expression was quantified by densitometry with Image J using GAPDH as a loading control. The results are derived from three litters and presented as mean ± SEM. ** p < 0.01, Student’s t- test.
Neutralizing Anti Lc1 Moab 1a, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/monoclonal+antibody+105/monoclonal+anti+lc+1+antibodies+lipo+105+1+b/pmc01905455-64-40-56
Average 90 stars, based on 1 article reviews
neutralizing anti-lc1 moab 1a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Tracon Inc humanized endoglin monoclonal antibody tracon 105
a Quantitation of endothelial cell permeability by measuring FITC-dextran changes across a HMEC-1 monolayer treated with 1 nM inhibin A in the presence or absence of (i) 100 μg/mL TRC105 or (ii) 10 ng/mL ALK1-Fc. FITC-dextran diffusion across the HMEC-1 monolayer at 4 h is presented. Mean ± SD, n = 4 for i and n = 3 for ii. n.s. not significant; *** p < 0.001; **** p < 0.0001. b Internalization of VE-cadherin measured by cell surface biotinylation. (i) Biotin labeling of cell surface proteins was performed on MEEC WT or MEEC ENG −/−. Internalization was induced by treatment with 1 nm Inhibin A for 30 min at 37 °C followed by stripping of cell surface biotin. Internalized VE-cadherin was detected by IP with neutravidin resin and (ii) immunoblotting with anti-VE-cadherin and (iii) quantitated as internalized VE-cadherin over input VE-cadherin normalized to 37 °C control. Mean ± SD, n = 2. n.s. not significant; * p < 0.05, unpaired t -test. c , d Patch/FRAP studies on the effect of inhibin A on <t>endoglin-ALK1</t> ( c ) and endoglin-ALK4 ( d ) complex formation. COS7 cells were transfected with myc-ALK1 and HA-endoglin ( c ) or with (each vector HA-ALK4 and myc-endoglin) (D) (each vector alone, or together). c After 24 h, singly transfected cells were labeled for FRAP by anti-tag Fab’ followed by fluorescent secondary Fab’ (Methods) and subjected to FRAP studies. For patch/FRAP, cells were subjected to protocol 1 of IgG-mediated patching/cross-linking (CL) (Methods), resulting in HA-endoglin patched and labeled by Alexa 488-GαR IgG (designated “CL: IgG αHA”), whereas myc-ALK1 is labeled by monovalent Fab’ (with secondary Alexa 546-GαM Fab’). In control experiments without HA-endoglin CL, the IgG labeling of the HA tag was replaced by exclusive Fab’ labeling. Where indicated, inhibin A (4 nM) was added during the fluorescent labeling step and maintained throughout the measurement. Representative FRAP curves are depicted in panels (i–iii), showing the lateral diffusion of singly expressed myc-ALK1 (i), singly expressed HA-endoglin immobilized by IgG CL (ii) and of myc-ALK1 in the presence of co-expressed and IgG-crosslinked HA-endoglin in the presence of inhibin A (iii). Panels (iv–v) depict average R f (iv) and D values (v) of multiple experiments. Bars represent mean ± SEM values, with the number of measurements (each conducted on a different cell) shown in each bar. Some of these numbers are lower in the D values panels, since only R f can be extracted from FRAP curves yielding less than 20% recovery. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets (**** p < 1 × 10 −15 ; *** p = 1 × 10 −9 ; one-way ANOVA followed by Bonferroni post-hoc test). d Cells were labeled for patch/FRAP using protocol 2 (Methods), leading to immobilization (CL) of the myc-endoglin and Fab’ labeling of HA-ALK4, whose lateral diffusion was then measured by FRAP. (i) Average R f values. (ii) Average D values. Bars are mean ± SEM with number of measurements ( n ) depicted in each bar. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets ( * *** p < 1 × 10 −15 ; ** p = 5.6 × 10 −3 ; one-way ANOVA followed by Bonferroni post-hoc test). No significant differences were found between D values following myc-endoglin immobilization.
Humanized Endoglin Monoclonal Antibody Tracon 105, supplied by Tracon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/monoclonal+antibody+105/humanized+endoglin+monoclonal+antibody+tracon+105/pmc09163327-230-23-19
Average 90 stars, based on 1 article reviews
humanized endoglin monoclonal antibody tracon 105 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
GeneTex a2b5 mouse monoclonal antibody [105]_#gtx14538
a Quantitation of endothelial cell permeability by measuring FITC-dextran changes across a HMEC-1 monolayer treated with 1 nM inhibin A in the presence or absence of (i) 100 μg/mL TRC105 or (ii) 10 ng/mL ALK1-Fc. FITC-dextran diffusion across the HMEC-1 monolayer at 4 h is presented. Mean ± SD, n = 4 for i and n = 3 for ii. n.s. not significant; *** p < 0.001; **** p < 0.0001. b Internalization of VE-cadherin measured by cell surface biotinylation. (i) Biotin labeling of cell surface proteins was performed on MEEC WT or MEEC ENG −/−. Internalization was induced by treatment with 1 nm Inhibin A for 30 min at 37 °C followed by stripping of cell surface biotin. Internalized VE-cadherin was detected by IP with neutravidin resin and (ii) immunoblotting with anti-VE-cadherin and (iii) quantitated as internalized VE-cadherin over input VE-cadherin normalized to 37 °C control. Mean ± SD, n = 2. n.s. not significant; * p < 0.05, unpaired t -test. c , d Patch/FRAP studies on the effect of inhibin A on <t>endoglin-ALK1</t> ( c ) and endoglin-ALK4 ( d ) complex formation. COS7 cells were transfected with myc-ALK1 and HA-endoglin ( c ) or with (each vector HA-ALK4 and myc-endoglin) (D) (each vector alone, or together). c After 24 h, singly transfected cells were labeled for FRAP by anti-tag Fab’ followed by fluorescent secondary Fab’ (Methods) and subjected to FRAP studies. For patch/FRAP, cells were subjected to protocol 1 of IgG-mediated patching/cross-linking (CL) (Methods), resulting in HA-endoglin patched and labeled by Alexa 488-GαR IgG (designated “CL: IgG αHA”), whereas myc-ALK1 is labeled by monovalent Fab’ (with secondary Alexa 546-GαM Fab’). In control experiments without HA-endoglin CL, the IgG labeling of the HA tag was replaced by exclusive Fab’ labeling. Where indicated, inhibin A (4 nM) was added during the fluorescent labeling step and maintained throughout the measurement. Representative FRAP curves are depicted in panels (i–iii), showing the lateral diffusion of singly expressed myc-ALK1 (i), singly expressed HA-endoglin immobilized by IgG CL (ii) and of myc-ALK1 in the presence of co-expressed and IgG-crosslinked HA-endoglin in the presence of inhibin A (iii). Panels (iv–v) depict average R f (iv) and D values (v) of multiple experiments. Bars represent mean ± SEM values, with the number of measurements (each conducted on a different cell) shown in each bar. Some of these numbers are lower in the D values panels, since only R f can be extracted from FRAP curves yielding less than 20% recovery. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets (**** p < 1 × 10 −15 ; *** p = 1 × 10 −9 ; one-way ANOVA followed by Bonferroni post-hoc test). d Cells were labeled for patch/FRAP using protocol 2 (Methods), leading to immobilization (CL) of the myc-endoglin and Fab’ labeling of HA-ALK4, whose lateral diffusion was then measured by FRAP. (i) Average R f values. (ii) Average D values. Bars are mean ± SEM with number of measurements ( n ) depicted in each bar. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets ( * *** p < 1 × 10 −15 ; ** p = 5.6 × 10 −3 ; one-way ANOVA followed by Bonferroni post-hoc test). No significant differences were found between D values following myc-endoglin immobilization.
A2b5 Mouse Monoclonal Antibody [105] #Gtx14538, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/monoclonal+antibody+105/a2b5+mouse+monoclonal+antibody++105+++gtx14538/pmc06712005__41398_2019_529_MOESM1_ESM-137-111-115
Average 90 stars, based on 1 article reviews
a2b5 mouse monoclonal antibody [105]_#gtx14538 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Diagnostic BioSystems anticd-105 monoclonal antibody sn6h
a Quantitation of endothelial cell permeability by measuring FITC-dextran changes across a HMEC-1 monolayer treated with 1 nM inhibin A in the presence or absence of (i) 100 μg/mL TRC105 or (ii) 10 ng/mL ALK1-Fc. FITC-dextran diffusion across the HMEC-1 monolayer at 4 h is presented. Mean ± SD, n = 4 for i and n = 3 for ii. n.s. not significant; *** p < 0.001; **** p < 0.0001. b Internalization of VE-cadherin measured by cell surface biotinylation. (i) Biotin labeling of cell surface proteins was performed on MEEC WT or MEEC ENG −/−. Internalization was induced by treatment with 1 nm Inhibin A for 30 min at 37 °C followed by stripping of cell surface biotin. Internalized VE-cadherin was detected by IP with neutravidin resin and (ii) immunoblotting with anti-VE-cadherin and (iii) quantitated as internalized VE-cadherin over input VE-cadherin normalized to 37 °C control. Mean ± SD, n = 2. n.s. not significant; * p < 0.05, unpaired t -test. c , d Patch/FRAP studies on the effect of inhibin A on <t>endoglin-ALK1</t> ( c ) and endoglin-ALK4 ( d ) complex formation. COS7 cells were transfected with myc-ALK1 and HA-endoglin ( c ) or with (each vector HA-ALK4 and myc-endoglin) (D) (each vector alone, or together). c After 24 h, singly transfected cells were labeled for FRAP by anti-tag Fab’ followed by fluorescent secondary Fab’ (Methods) and subjected to FRAP studies. For patch/FRAP, cells were subjected to protocol 1 of IgG-mediated patching/cross-linking (CL) (Methods), resulting in HA-endoglin patched and labeled by Alexa 488-GαR IgG (designated “CL: IgG αHA”), whereas myc-ALK1 is labeled by monovalent Fab’ (with secondary Alexa 546-GαM Fab’). In control experiments without HA-endoglin CL, the IgG labeling of the HA tag was replaced by exclusive Fab’ labeling. Where indicated, inhibin A (4 nM) was added during the fluorescent labeling step and maintained throughout the measurement. Representative FRAP curves are depicted in panels (i–iii), showing the lateral diffusion of singly expressed myc-ALK1 (i), singly expressed HA-endoglin immobilized by IgG CL (ii) and of myc-ALK1 in the presence of co-expressed and IgG-crosslinked HA-endoglin in the presence of inhibin A (iii). Panels (iv–v) depict average R f (iv) and D values (v) of multiple experiments. Bars represent mean ± SEM values, with the number of measurements (each conducted on a different cell) shown in each bar. Some of these numbers are lower in the D values panels, since only R f can be extracted from FRAP curves yielding less than 20% recovery. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets (**** p < 1 × 10 −15 ; *** p = 1 × 10 −9 ; one-way ANOVA followed by Bonferroni post-hoc test). d Cells were labeled for patch/FRAP using protocol 2 (Methods), leading to immobilization (CL) of the myc-endoglin and Fab’ labeling of HA-ALK4, whose lateral diffusion was then measured by FRAP. (i) Average R f values. (ii) Average D values. Bars are mean ± SEM with number of measurements ( n ) depicted in each bar. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets ( * *** p < 1 × 10 −15 ; ** p = 5.6 × 10 −3 ; one-way ANOVA followed by Bonferroni post-hoc test). No significant differences were found between D values following myc-endoglin immobilization.
Anticd 105 Monoclonal Antibody Sn6h, supplied by Diagnostic BioSystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/monoclonal+antibody+105/anticd+105+monoclonal+antibody+sn6h/pm17334712-29-7-11
Average 90 stars, based on 1 article reviews
anticd-105 monoclonal antibody sn6h - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Antibodies Inc anti-kv1.1 k+ channel (external) antibody
a Quantitation of endothelial cell permeability by measuring FITC-dextran changes across a HMEC-1 monolayer treated with 1 nM inhibin A in the presence or absence of (i) 100 μg/mL TRC105 or (ii) 10 ng/mL ALK1-Fc. FITC-dextran diffusion across the HMEC-1 monolayer at 4 h is presented. Mean ± SD, n = 4 for i and n = 3 for ii. n.s. not significant; *** p < 0.001; **** p < 0.0001. b Internalization of VE-cadherin measured by cell surface biotinylation. (i) Biotin labeling of cell surface proteins was performed on MEEC WT or MEEC ENG −/−. Internalization was induced by treatment with 1 nm Inhibin A for 30 min at 37 °C followed by stripping of cell surface biotin. Internalized VE-cadherin was detected by IP with neutravidin resin and (ii) immunoblotting with anti-VE-cadherin and (iii) quantitated as internalized VE-cadherin over input VE-cadherin normalized to 37 °C control. Mean ± SD, n = 2. n.s. not significant; * p < 0.05, unpaired t -test. c , d Patch/FRAP studies on the effect of inhibin A on <t>endoglin-ALK1</t> ( c ) and endoglin-ALK4 ( d ) complex formation. COS7 cells were transfected with myc-ALK1 and HA-endoglin ( c ) or with (each vector HA-ALK4 and myc-endoglin) (D) (each vector alone, or together). c After 24 h, singly transfected cells were labeled for FRAP by anti-tag Fab’ followed by fluorescent secondary Fab’ (Methods) and subjected to FRAP studies. For patch/FRAP, cells were subjected to protocol 1 of IgG-mediated patching/cross-linking (CL) (Methods), resulting in HA-endoglin patched and labeled by Alexa 488-GαR IgG (designated “CL: IgG αHA”), whereas myc-ALK1 is labeled by monovalent Fab’ (with secondary Alexa 546-GαM Fab’). In control experiments without HA-endoglin CL, the IgG labeling of the HA tag was replaced by exclusive Fab’ labeling. Where indicated, inhibin A (4 nM) was added during the fluorescent labeling step and maintained throughout the measurement. Representative FRAP curves are depicted in panels (i–iii), showing the lateral diffusion of singly expressed myc-ALK1 (i), singly expressed HA-endoglin immobilized by IgG CL (ii) and of myc-ALK1 in the presence of co-expressed and IgG-crosslinked HA-endoglin in the presence of inhibin A (iii). Panels (iv–v) depict average R f (iv) and D values (v) of multiple experiments. Bars represent mean ± SEM values, with the number of measurements (each conducted on a different cell) shown in each bar. Some of these numbers are lower in the D values panels, since only R f can be extracted from FRAP curves yielding less than 20% recovery. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets (**** p < 1 × 10 −15 ; *** p = 1 × 10 −9 ; one-way ANOVA followed by Bonferroni post-hoc test). d Cells were labeled for patch/FRAP using protocol 2 (Methods), leading to immobilization (CL) of the myc-endoglin and Fab’ labeling of HA-ALK4, whose lateral diffusion was then measured by FRAP. (i) Average R f values. (ii) Average D values. Bars are mean ± SEM with number of measurements ( n ) depicted in each bar. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets ( * *** p < 1 × 10 −15 ; ** p = 5.6 × 10 −3 ; one-way ANOVA followed by Bonferroni post-hoc test). No significant differences were found between D values following myc-endoglin immobilization.
Anti Kv1.1 K+ Channel (External) Antibody, supplied by Antibodies Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/monoclonal+antibody+105/Anti-Kv1%2E1+K%2B+Channel+(External)+Antibody/custom%4075-105%4026840208
Average 93 stars, based on 1 article reviews
anti-kv1.1 k+ channel (external) antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

N/A
HCV NS5B RdRp 92 105 mouse monoclonal antibody clone 6B12 Aff Purified
  Buy from Supplier

N/A
CD25 Monoclonal Antibody for IF, Flow, ELISA
  Buy from Supplier

N/A
GUSB Monoclonal Antibody for Western Blot, IHC (F), ELISA
  Buy from Supplier

N/A
A2B5 Monoclonal Antibody for Western Blot, IF, ICC, IHC, Flow
  Buy from Supplier

Image Search Results


Immunoblotting shows that loss of CDKL5 reduces the level of phosphorylated KCC2 at serine 940 (pKCC2-S940; A, B) in the rostral cortex at P12. No significant alteration is found in protein expression of total KCC2, phosphorylated KCC2 at threonine 1007 (pKCC2-T1007), NKCC1 and GABA A receptor. The reduction of PSD-95 in Cdkl5 -/y pups (A, D), consistent with the findings reported previously, serves as a positive control. The protein expression was quantified by densitometry with Image J using GAPDH as a loading control. The results are derived from three litters and presented as mean ± SEM. ** p < 0.01, Student’s t- test.

Journal: bioRxiv

Article Title: Deficiency of cyclin-dependent kinase-like 5 causes spontaneous epileptic seizures in neonatal mice

doi: 10.1101/2020.03.09.983981

Figure Lengend Snippet: Immunoblotting shows that loss of CDKL5 reduces the level of phosphorylated KCC2 at serine 940 (pKCC2-S940; A, B) in the rostral cortex at P12. No significant alteration is found in protein expression of total KCC2, phosphorylated KCC2 at threonine 1007 (pKCC2-T1007), NKCC1 and GABA A receptor. The reduction of PSD-95 in Cdkl5 -/y pups (A, D), consistent with the findings reported previously, serves as a positive control. The protein expression was quantified by densitometry with Image J using GAPDH as a loading control. The results are derived from three litters and presented as mean ± SEM. ** p < 0.01, Student’s t- test.

Article Snippet: The membranes were blocked using 5% skim milk for 1 h and then incubated with primary antibodies against CDKL5 (1:1,000, Abcam), K + /Cl - co-transporter 2 (KCC2; 1:1,000, Millipore), phosphorylated KCC2 at serine 940 (pKCC2-S940; 1:5,000, PhosphoSolutions), phosphorylated KCC2 at threonine 1007 (pKCC2-T1007; 1:5,000, PhosphoSolutions), Na + /K + /Cl - co-transporter 1 (NKCC1; 1:10,000, Millipore), postsynaptic density protein 95 (PSD-95; 1:2,000, ThermoFisher), GABA A R-gamma 2 (GABA A R; 1:2,000, Millipore), glutamate decarboxylase 2 (GAD2; 1:1,000, Cell Signaling), cannabinoid receptor 1 (CB1R; 1:5,000, Abcam), vesicular GABA transporter (VGAT; 1:1,000, SYSY), vesicular glutamate transporter 2 (VGLUT2; 1:1,000, SYSY) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 1:50,000, Millipore) at 4 °C for 16 h. Following incubation with peroxidase-conjugated secondary antibodies at room temperature for 2 h, the target proteins were detected by an enhanced chemoluminescence reagent (ECL, Millipore) with an image acquisition system (Biostep, Germany).

Techniques: Western Blot, Expressing, Positive Control, Control, Derivative Assay

a Quantitation of endothelial cell permeability by measuring FITC-dextran changes across a HMEC-1 monolayer treated with 1 nM inhibin A in the presence or absence of (i) 100 μg/mL TRC105 or (ii) 10 ng/mL ALK1-Fc. FITC-dextran diffusion across the HMEC-1 monolayer at 4 h is presented. Mean ± SD, n = 4 for i and n = 3 for ii. n.s. not significant; *** p < 0.001; **** p < 0.0001. b Internalization of VE-cadherin measured by cell surface biotinylation. (i) Biotin labeling of cell surface proteins was performed on MEEC WT or MEEC ENG −/−. Internalization was induced by treatment with 1 nm Inhibin A for 30 min at 37 °C followed by stripping of cell surface biotin. Internalized VE-cadherin was detected by IP with neutravidin resin and (ii) immunoblotting with anti-VE-cadherin and (iii) quantitated as internalized VE-cadherin over input VE-cadherin normalized to 37 °C control. Mean ± SD, n = 2. n.s. not significant; * p < 0.05, unpaired t -test. c , d Patch/FRAP studies on the effect of inhibin A on endoglin-ALK1 ( c ) and endoglin-ALK4 ( d ) complex formation. COS7 cells were transfected with myc-ALK1 and HA-endoglin ( c ) or with (each vector HA-ALK4 and myc-endoglin) (D) (each vector alone, or together). c After 24 h, singly transfected cells were labeled for FRAP by anti-tag Fab’ followed by fluorescent secondary Fab’ (Methods) and subjected to FRAP studies. For patch/FRAP, cells were subjected to protocol 1 of IgG-mediated patching/cross-linking (CL) (Methods), resulting in HA-endoglin patched and labeled by Alexa 488-GαR IgG (designated “CL: IgG αHA”), whereas myc-ALK1 is labeled by monovalent Fab’ (with secondary Alexa 546-GαM Fab’). In control experiments without HA-endoglin CL, the IgG labeling of the HA tag was replaced by exclusive Fab’ labeling. Where indicated, inhibin A (4 nM) was added during the fluorescent labeling step and maintained throughout the measurement. Representative FRAP curves are depicted in panels (i–iii), showing the lateral diffusion of singly expressed myc-ALK1 (i), singly expressed HA-endoglin immobilized by IgG CL (ii) and of myc-ALK1 in the presence of co-expressed and IgG-crosslinked HA-endoglin in the presence of inhibin A (iii). Panels (iv–v) depict average R f (iv) and D values (v) of multiple experiments. Bars represent mean ± SEM values, with the number of measurements (each conducted on a different cell) shown in each bar. Some of these numbers are lower in the D values panels, since only R f can be extracted from FRAP curves yielding less than 20% recovery. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets (**** p < 1 × 10 −15 ; *** p = 1 × 10 −9 ; one-way ANOVA followed by Bonferroni post-hoc test). d Cells were labeled for patch/FRAP using protocol 2 (Methods), leading to immobilization (CL) of the myc-endoglin and Fab’ labeling of HA-ALK4, whose lateral diffusion was then measured by FRAP. (i) Average R f values. (ii) Average D values. Bars are mean ± SEM with number of measurements ( n ) depicted in each bar. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets ( * *** p < 1 × 10 −15 ; ** p = 5.6 × 10 −3 ; one-way ANOVA followed by Bonferroni post-hoc test). No significant differences were found between D values following myc-endoglin immobilization.

Journal: Communications Biology

Article Title: Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers

doi: 10.1038/s42003-022-03495-6

Figure Lengend Snippet: a Quantitation of endothelial cell permeability by measuring FITC-dextran changes across a HMEC-1 monolayer treated with 1 nM inhibin A in the presence or absence of (i) 100 μg/mL TRC105 or (ii) 10 ng/mL ALK1-Fc. FITC-dextran diffusion across the HMEC-1 monolayer at 4 h is presented. Mean ± SD, n = 4 for i and n = 3 for ii. n.s. not significant; *** p < 0.001; **** p < 0.0001. b Internalization of VE-cadherin measured by cell surface biotinylation. (i) Biotin labeling of cell surface proteins was performed on MEEC WT or MEEC ENG −/−. Internalization was induced by treatment with 1 nm Inhibin A for 30 min at 37 °C followed by stripping of cell surface biotin. Internalized VE-cadherin was detected by IP with neutravidin resin and (ii) immunoblotting with anti-VE-cadherin and (iii) quantitated as internalized VE-cadherin over input VE-cadherin normalized to 37 °C control. Mean ± SD, n = 2. n.s. not significant; * p < 0.05, unpaired t -test. c , d Patch/FRAP studies on the effect of inhibin A on endoglin-ALK1 ( c ) and endoglin-ALK4 ( d ) complex formation. COS7 cells were transfected with myc-ALK1 and HA-endoglin ( c ) or with (each vector HA-ALK4 and myc-endoglin) (D) (each vector alone, or together). c After 24 h, singly transfected cells were labeled for FRAP by anti-tag Fab’ followed by fluorescent secondary Fab’ (Methods) and subjected to FRAP studies. For patch/FRAP, cells were subjected to protocol 1 of IgG-mediated patching/cross-linking (CL) (Methods), resulting in HA-endoglin patched and labeled by Alexa 488-GαR IgG (designated “CL: IgG αHA”), whereas myc-ALK1 is labeled by monovalent Fab’ (with secondary Alexa 546-GαM Fab’). In control experiments without HA-endoglin CL, the IgG labeling of the HA tag was replaced by exclusive Fab’ labeling. Where indicated, inhibin A (4 nM) was added during the fluorescent labeling step and maintained throughout the measurement. Representative FRAP curves are depicted in panels (i–iii), showing the lateral diffusion of singly expressed myc-ALK1 (i), singly expressed HA-endoglin immobilized by IgG CL (ii) and of myc-ALK1 in the presence of co-expressed and IgG-crosslinked HA-endoglin in the presence of inhibin A (iii). Panels (iv–v) depict average R f (iv) and D values (v) of multiple experiments. Bars represent mean ± SEM values, with the number of measurements (each conducted on a different cell) shown in each bar. Some of these numbers are lower in the D values panels, since only R f can be extracted from FRAP curves yielding less than 20% recovery. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets (**** p < 1 × 10 −15 ; *** p = 1 × 10 −9 ; one-way ANOVA followed by Bonferroni post-hoc test). d Cells were labeled for patch/FRAP using protocol 2 (Methods), leading to immobilization (CL) of the myc-endoglin and Fab’ labeling of HA-ALK4, whose lateral diffusion was then measured by FRAP. (i) Average R f values. (ii) Average D values. Bars are mean ± SEM with number of measurements ( n ) depicted in each bar. Asterisks indicate significant differences between the R f values of the pairs indicated by brackets ( * *** p < 1 × 10 −15 ; ** p = 5.6 × 10 −3 ; one-way ANOVA followed by Bonferroni post-hoc test). No significant differences were found between D values following myc-endoglin immobilization.

Article Snippet: To evaluate if ALK1 and endoglin are required for inhibin’s influence on vascular permeability, we treated HMEC-1 cells with Tracon 105 (TRC105), a humanized endoglin monoclonal antibody , or with ALK1-Fc, a human chimeric ALK1 protein (Fig. ).

Techniques: Quantitation Assay, Permeability, Diffusion-based Assay, Labeling, Stripping Membranes, Western Blot, Control, Transfection, Plasmid Preparation